Stocks TelegraphStocks Telegraph
Stock Ideas

DNA Financial Statements and Analysis

NYSE : DNA

Ginkgo Bioworks

$10.10
1.78+21.39%
At Close 4:00 PM
56.2
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
revenue38.837M49.604M48.318M89.046M56.206M
cost of revenue12.802M14.822M12.047M9.987M31.051M
gross profit26.035M34.782M36.271M79.059M25.155M
gross profit ratio0.670.7010.7510.8880.448
research and development expenses69.353M53.37M70.923M77.006M134.221M
general and administrative expenses44.954M43.279M49.043M52.292M66.285M
selling and marketing expenses00000
selling general and administrative expenses44.954M43.279M49.043M52.292M66.285M
other expenses1.745M3.674M5.273M4.965M64.924M
operating expenses116.052M100.323M125.239M134.263M267.344M
cost and expenses128.854M115.145M137.286M144.25M279.151M
interest income5.742M6.083M6.081M9.251M10.313M
interest expense00000
depreciation and amortization14.168M15.793M15.366M17.169M17.33M
ebitda-66.586M-46.074M-68.329M-35.93M-136.945M
ebitda ratio-1.714-0.929-1.414-0.403-2.436
operating income-90.017M-65.541M-88.968M-55.204M-222.945M
operating income ratio-2.318-1.321-1.841-0.62-3.967
total other income expenses net9.263M4.958M-1.901M-1.574M5.954M
income before tax-80.754M-60.583M-90.869M-56.778M-216.991M
income before tax ratio-2.079-1.221-1.881-0.638-3.861
income tax expense1.00K-283.00K88.00K-375.00K190.00K
net income-80.755M-60.30M-90.957M-56.403M-217.181M
net income ratio-2.079-1.216-1.882-0.633-3.864
eps-1.45-1.10-1.68-1.08-4.23
eps diluted-1.45-1.10-1.68-1.08-4.23
weighted average shs out55.634M54.859M54.242M52.24M51.37M
weighted average shs out dil55.634M54.859M54.242M52.246M51.376M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
cash and cash equivalents111.065M203.566M312.42M616.214M730.367M
short term investments350.797M270.125M204.502M057.796M
cash and short term investments461.862M473.691M516.922M616.214M730.367M
net receivables21.43M23.126M27.17M23.411M18.891M
inventory00000
other current assets22.79M26.208M20.442M22.855M34.104M
total current assets506.082M523.025M564.534M662.48M783.362M
property plant equipment net544.792M562.15M581.222M616.946M628.59M
goodwill00000
intangible assets61.522M66.152M68.756M79.566M90.602M
goodwill and intangible assets61.522M66.152M68.756M79.566M90.602M
long term investments30.175M32.446M31.962M62.103M62.49M
tax assets00000
other non current assets46.594M47.236M46.989M59.788M60.211M
total non current assets683.083M707.984M728.929M818.403M841.893M
other assets00000
total assets1.189B1.231B1.293B1.481B1.625B
account payables10.704M11.202M11.267M15.70M23.029M
short term debt00000
tax payables00000
deferred revenue25.236M28.287M33.653M22.894M26.007M
other current liabilities79.341M57.231M70.747M75.833M117.118M
total current liabilities115.281M96.72M115.667M114.427M166.154M
long term debt422.87M428.827M434.561M445.592M452.265M
deferred revenue non current074.566M80.378M0152.869M
deferred tax liabilities non current00000
other non current liabilities91.231M17.944M15.43M122.921M20.895M
total non current liabilities514.101M521.337M530.369M568.513M626.029M
other liabilities00000
capital lease obligations422.87M428.827M434.561M445.592M452.265M
total liabilities629.382M618.057M646.036M682.94M792.183M
preferred stock00000
common stock6.00K6.00K5.00K5.00K206.00K
retained earnings-6.07B-5.989B-5.929B-5.73B-5.674B
accumulated other comprehensive income loss1.996M1.653M-850.00K263.00K-1.723M
other total stockholders equity6.627B6.60B6.577B6.528B6.508B
total stockholders equity559.783M612.952M647.427M797.943M833.072M
total equity559.783M612.952M647.427M797.943M833.072M
total liabilities and stockholders equity1.189B1.231B1.293B1.481B1.625B
minority interest00000
total investments380.972M302.571M236.464M62.103M120.286M
total debt422.87M428.827M434.561M445.592M452.265M
net debt311.805M225.261M122.141M-170.622M-278.102M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Jun 30, 2024Mar 31, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q2Q1
deferred income tax00000
stock based compensation17.841M22.247M20.431M37.146M40.782M
change in working capital13.777M-22.713M-11.565M5.88M312.00K
accounts receivables757.00K4.281M-4.693M5.668M-6.77M
inventory00000
accounts payables0-11.544M6.419M-7.00K10.871M
other working capital13.02M-15.45M-13.291M219.00K-3.789M
other non cash items3.363M4.719M15.204M138.58M85.108M
net cash provided by operating activities-31.606M-40.254M-51.521M-84.39M-89.259M
investments in property plant and equipment0-38.00K-7.622M-27.032M-6.71M
acquisitions net000191.00K-5.40M
purchases of investments-81.706M-128.95M-191.182M00
sales maturities of investments8.641M64.958M000
other investing activites249.00K142.00K120.00K191.00K0
net cash used for investing activites-72.816M-63.888M-198.684M-26.841M-12.11M
debt repayment-24.00K-98.00K-207.00K-200.00K-294.00K
common stock issued00014.00K70.00K
common stock repurchased00000
dividends paid00000
other financing activites9.962M00-40.00K-621.00K
net cash used provided by financing activities9.938M-98.00K-207.00K-226.00K-845.00K
effect of forex changes on cash93.00K-1.608M74.00K-16.00K-157.00K
net change in cash-94.391M-105.848M-250.338M-111.048M-105.094M
cash at end of period156.96M214.515M355.405M732.72M843.768M
cash at beginning of period251.351M320.363M605.743M843.768M948.862M
operating cashflow-31.606M-40.254M-51.521M-84.39M-89.259M
capital expenditure0-38.00K-7.622M-27.032M-6.71M
free cash flow-31.606M-40.292M-59.143M-111.422M-95.969M
Graph

Frequently Asked Questions

How did Ginkgo Bioworks Holdings, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, DNA generated $38.84M in revenue last quarter, while its costs came in at $12.80M.
Last quarter, how much Gross Profit did Ginkgo Bioworks Holdings, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Ginkgo Bioworks Holdings, Inc. reported a $26.04M Gross Profit for the quarter ended Sep 30, 2025.
Have DNA's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. DNA incurred $116.05M worth of Operating Expenses, while it generated -$90.02M worth of Operating Income.
How much Net Income has DNA posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Ginkgo Bioworks Holdings, Inc., the company generated -$80.76M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Ginkgo Bioworks Holdings, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Ginkgo Bioworks Holdings, Inc. as of the end of the last quarter was $111.07M.
What are DNA's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, DNA had Total Net Receivables of $21.43M.
In terms of Total Assets and Current Assets, where did Ginkgo Bioworks Holdings, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of DNA were $506.08M, while the Total Assets stand at $1.19B.
As of the last quarter, how much Total Debt did Ginkgo Bioworks Holdings, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of DNA's debt was $422.87M at the end of the last quarter.
What were DNA's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, DNA reported total liabilities of $629.38M.
How much did DNA's Working Capital change over the last quarter?
Working Capital Change for DNA was $13.78M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
DNA generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. DNA generated -$31.61M of Cash from Operating Activities during its recently reported quarter.
What was DNA's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. DNA reported a -$94.39M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph